ArticleFrontiers in immunology2026
Clinical features and outcomes of atezolizumab-associated encephalitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the clinical characteristics of atezolizumab-associated encephalitis and to provide clinical evidence for diagnosis and treatment. Methods: Clinical reports on atezolizumab-associated encephalitis published before June 30, 2026 were collected for retrospective analysis by searching Chinese and English databases. Results: A total of 39 cases of encephalitis were included, with a median age of 60 years (33, 78). The median time of symptom onset was 14 days (2, 420) after the initial administration. Fever (53.8%), confusion (51.3%) and headache (28.2%) were the main complaints of the patients. Cerebrospinal fluid examination showed elevated white blood cell count and protein, with median values of 27 cells/μL (1, 553) and 133mg/dL (27.1, 815), respectively. Brain magnetic resonance imaging showed T2 fluid-attenuated inversion recovery hyperintensities in half of the patients. Electroencephalogram showed display epileptiform discharges (26.7%) and slow waves (40.0%). After discontinuation of atezolizumab and initiation of targeted treatment, 97.4% of patients achieved symptomatic improvement or recovery, while 2.6% died of encephalitis-related complications. Conclusion: Patients with atezolizumab-associated encephalitis were predominantly middle-aged and elderly, with fever, confusion and headache as the major manifestations. Clinicians should be alert to the potential risk of encephalitis during atezolizumab treatment. Most patients obtained symptom relief or clinical recovery following atezolizumab discontinuation and treatment; only a few succumbed to severe encephalitis-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.